Clinical Trial Update: Trial for Treatment Refractory Trigeminal Neuralgia [Phase 2]

View source ↗

Summary

A Pfizer-sponsored Phase 2 trial for treatment-refractory trigeminal neuralgia was terminated, with results posted in June 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Trigeminal Neuralgia

Snippet

Sponsor: Pfizer | Conditions: Trigeminal Neuralgia | Phase 2 | Status: TERMINATED | Results posted: 2024-06-10